Last reviewed · How we verify
Sofosbuvir/Ledipasvir plus Ribavirin 24W
Sofosbuvir inhibits HCV NS5B polymerase while ledipasvir inhibits HCV NS5A protein, and ribavirin enhances viral clearance through multiple mechanisms to achieve sustained virologic response in hepatitis C.
Sofosbuvir inhibits HCV NS5B polymerase while ledipasvir inhibits HCV NS5A protein, and ribavirin enhances viral clearance through multiple mechanisms to achieve sustained virologic response in hepatitis C. Used for Chronic hepatitis C virus infection (genotype 1-6), Treatment-experienced and treatment-naïve patients with hepatitis C.
At a glance
| Generic name | Sofosbuvir/Ledipasvir plus Ribavirin 24W |
|---|---|
| Sponsor | Iran Hepatitis Network |
| Drug class | Direct-acting antiviral (DAA) combination |
| Target | HCV NS5B polymerase, HCV NS5A protein |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | Phase 3 |
Mechanism of action
Sofosbuvir is a nucleotide analog that directly inhibits the hepatitis C virus RNA-dependent RNA polymerase (NS5B), blocking viral replication. Ledipasvir is a non-structural protein 5A (NS5A) inhibitor that prevents viral protein complex formation and RNA replication. Ribavirin is a nucleoside analog that increases mutation rates in the viral genome and enhances immune responses, working synergistically with the direct-acting antivirals.
Approved indications
- Chronic hepatitis C virus infection (genotype 1-6)
- Treatment-experienced and treatment-naïve patients with hepatitis C
Common side effects
- Fatigue
- Headache
- Nausea
- Anemia (ribavirin-related)
- Insomnia
- Diarrhea
Key clinical trials
- Treatment of Hepatitis C Virus Infection With Generic Sofosbuvir/Ledipasvir in Iranian Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: